{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:50:50Z","timestamp":1782226250613,"version":"3.54.5"},"reference-count":23,"publisher":"Galenos Yayinevi","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turk Gogus Kalp Dama"],"accepted":{"date-parts":[[2024,10,18]]},"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:italic>Background:<\/jats:italic>\n                    <\/jats:bold>\n                    This study aimed to investigate whether there is a correlation between some serum inflammatory markers and the survival of patients with malignant pleural effusions (MPEs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Methods:<\/jats:italic>\n                    <\/jats:bold>\n                    The prospective study included 125 patients (67 males, 58 females; median age: 62 years; range, 40 to 92 years) who underwent thoracentesis for pleural effusion between January 2020 and December 2021. An overall survival analysis was performed, and survival differences between the groups were investigated. The cutoff value of the inflammatory parameters associated with mortality was determined by receiver operating characteristic analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Results:<\/jats:italic>\n                    <\/jats:bold>\n                    Median survival after detection of MPE was six months, and three- and five-year overall survivals were 16% and 4%, respectively. There was a significant correlation between the ECOG (Eastern Cooperative Oncology Group) score of the patients and the median survival. Serum C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), fluid albumin, and serum lactate dehydrogenase (LDH)-to-pleural LDH ratio and survival had a statistically significant relationship in receiver operating characteristic analysis. Threshold values were determined accordingly. Poor prognostic factors that were found to be statistically significant were high CRP (p=0.001), high NLR (p=0.001), high PLR (p=0.02), and high serum LDH-to-pleural LDH ratio (p=0.04).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Conclusion:<\/jats:italic>\n                    <\/jats:bold>\n                    Some serum inflammatory markers, including high CRP, high NLR, high PLR, and high serum LDH-to-pleural LDH ratio, can be a simple and inexpensive method in predicting prognosis in patients with MPE.\n                  <\/jats:p>","DOI":"10.5606\/tgkdc.dergisi.2024.26905","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:22:20Z","timestamp":1731043340000},"page":"445-452","source":"Crossref","is-referenced-by-count":1,"title":["Can some inflammatory parameters predict the survival of patients with malignant pleural effusion?"],"prefix":"10.4274","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7149-5982","authenticated-orcid":false,"given":"Nur","family":"Dilvin Ozkan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5754-2677","authenticated-orcid":false,"given":"Aynur","family":"Bas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8695-7855","authenticated-orcid":false,"given":"Axel","family":"Scheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-5417","authenticated-orcid":false,"given":"Melanie","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4522-1731","authenticated-orcid":false,"given":"Tomas","family":"Bohanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6842-0907","authenticated-orcid":false,"given":"Elisabeth","family":"Stubenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5402-9031","authenticated-orcid":false,"given":"Muhammet","family":"Sayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-010X","authenticated-orcid":false,"given":"Ismail","family":"Cuneyt Kurul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6563-5643","authenticated-orcid":false,"given":"Ghanim","family":"Bahil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-6492","authenticated-orcid":false,"given":"Ali","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: From bench to bedside. Eur Respir Rev 2016;25:189-98. doi: 10.1183\/16000617.0019-2016.","DOI":"10.1183\/16000617.0019-2016"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Jacobs B, Sheikh G, Youness HA, Keddissi JI, Abdo T. Diagnosis and management of malignant pleural effusion: A decade in review. Diagnostics (Basel) 2022;12:1016. doi: 10.3390\/diagnostics12041016.","DOI":"10.3390\/diagnostics12041016"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature 2008;454:436-44. doi: 10.1038\/ nature07205.","DOI":"10.1038\/nature07205"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Sayan M, Kankoc A, Ozkan ND, Bas A, Celik A, Kurul IC, et al. Simple peripheral blood cell parameters to predict prognosis in non-small cell lung cancer. Indian J Surg 2021;83:170-5.","DOI":"10.1007\/s12262-020-02237-4"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Gayaf M, Anar C, Canbaz M, Do\u011fan B\u0130, Erbaycu AE, G\u00fcldaval F. Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil\/lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion? Tuberk Toraks 2021;69:133-43. English. doi: 10.5578\/tt.20219802.","DOI":"10.5578\/tt.20219802"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Sayan M, Akarsu I, Tombul I, Kankoc A, Ozkan D, Valiyev E, et al. The prognostic significance of the systemic immuneinflammatory index in surgically treated non-small cell lung cancers. Current Thoracic Surgery 2020;5:103-7. doi: 10.26663\/cts.2020.00022","DOI":"10.26663\/cts.2020.00022"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Putnam JB Jr. Malignant pleural effusions. Surg Clin North Am 2002;82:867-83. doi: 10.1016\/s0039-6109(02)00036-1.","DOI":"10.1016\/S0039-6109(02)00036-1"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with smallcell lung cancer? Oncotarget 2017;8:37200-7. doi: 10.18632\/ oncotarget.16553.","DOI":"10.18632\/oncotarget.16553"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Lan H, Zhou L, Chi D, Zhou Q, Tang X, Zhu D, et al. Preoperative platelet to lymphocyte and neutrophil to lymphocyte ratios are independent prognostic factors for  patients undergoing lung cancer radical surgery: A single institutional cohort study. Oncotarget 2017;8:35301-10. doi: 10.18632\/oncotarget.13312.","DOI":"10.18632\/oncotarget.13312"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Zhang X, Duan J, Wen Z, Xiong H, Chen X, Liu Y, et al. Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR\/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and meta-analysis. Front Oncol 2021;11:766672. doi: 10.3389\/ fonc.2021.766672.","DOI":"10.3389\/fonc.2021.766672"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Que H, Fu Q, Lan T, Tian X, Wei X. Tumor-associated neutrophils and neutrophil-targeted cancer therapies. Biochim Biophys Acta Rev Cancer 2022;1877:188762. doi: 10.1016\/j.bbcan.2022.188762.","DOI":"10.1016\/j.bbcan.2022.188762"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Leslie M. Cell biology. Beyond clotting: The powers of platelets. Science 2010;328:562-4. doi: 10.1126\/ science.328.5978.562.","DOI":"10.1126\/science.328.5978.562"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Que Y, Qiu H, Li Y, Chen Y, Xiao W, Zhou Z, et al. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for softtissue sarcoma. BMC Cancer 2015;15:648.","DOI":"10.1186\/s12885-015-1654-6"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Pan YC, Jia ZF, Cao DH, Wu YH, Jiang J, Wen SM, et al. Preoperative Lymphocyte-to-Monocyte Ratio (LMR) could independently predict overall survival of resectable gastric cancer patients. Medicine (Baltimore) 2018;97:e13896. doi: 10.1097\/MD.0000000000013896.","DOI":"10.1097\/MD.0000000000013896"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and metaanalysis. Cancer Treat Rev 2015;41:971-8. doi: 10.1016\/j. ctrv.2015.10.003.","DOI":"10.1016\/j.ctrv.2015.10.003"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Lu C, Chen Q, Li J, Wang C, Yu L. The prognostic role of Lymphocyte to Monocyte Ratio (LMR) in patients with Myelodysplastic Neoplasms. Hematology 2023;28:2210929. doi: 10.1080\/16078454.2023.2210929.","DOI":"10.1080\/16078454.2023.2210929"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and metaanalysis. Cancer Treat Rev 2015;41:971-8. doi: 10.1016\/j. ctrv.2015.10.003.","DOI":"10.1016\/j.ctrv.2015.10.003"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Hutterer GC, Stoeckigt C, Stojakovic T, Jesche J, Eberhard K, Pummer K, et al. Low preoperative LymphocyteMonocyte Ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinoma. Urol Oncol 2014;32:1041-8. doi: 10.1016\/j. urolonc.2014.04.001.","DOI":"10.1016\/j.urolonc.2014.04.001"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Amin Z, Iskandar SD, Sibli. Prognostic factors of 30-day survival of patients with malignant pleural effusion. Indian J Palliat Care 2017;23:321-4. doi: 10.4103\/IJPC.IJPC_2_17.","DOI":"10.4103\/IJPC.IJPC_2_17"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Lossos IS, Intrator O, Berkman N, Breuer R. Lactate dehydrogenase isoenzyme analysis for the diagnosis of pleural effusion in haemato-oncological patients. Respir Med 1999;93:338-41. doi: 10.1016\/s0954-6111(99)90315-3.","DOI":"10.1016\/S0954-6111(99)90315-3"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS\/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg 2019;55:116-32. doi: 10.1093\/ejcts\/ ezy258.","DOI":"10.1093\/ejcts\/ezy258"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Xu Y, Ma K, Zhang F, Ma M, Hong L, Wang J, et al. Association between baseline C reactive protein level and survival outcomes for cancer patients treated with immunotherapy: A meta analysis. Exp Ther Med 2023;26:361. doi: 10.3892\/ etm.2023.12060.","DOI":"10.3892\/etm.2023.12060"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Adachi M, Nakayama M, Matsumoto S, Shima Y, Uemaetomari I, Yoshimura T, et al. Elevation of C-reactive protein during concurrent chemoradiotherapy is a poor predictive factor for head and neck cancer. Auris Nasus Larynx 2023;50:601-6. doi: 10.1016\/j.anl.2022.12.014.","DOI":"10.1016\/j.anl.2022.12.014"}],"container-title":["Turkish Journal of Thoracic and Cardiovascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tgkdc.dergisi.org\/uploads\/pdf\/pdf_TGKDC_3826.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/tgkdc.dergisi.org\/uploads\/pdf\/pdf_TGKDC_3826.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:52:36Z","timestamp":1782222756000},"score":1,"resource":{"primary":{"URL":"https:\/\/tjtcvs.org\/articles\/doi\/tgkdc.dergisi.2024.26905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.5606\/tgkdc.dergisi.2024.26905","relation":{},"ISSN":["1301-5680","2149-8156"],"issn-type":[{"value":"1301-5680","type":"print"},{"value":"2149-8156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}